Research using psychedelic drugs for therapeutic purposes has faced a number of regulatory obstacles unlike other treatments in the mental health field, including widespread skepticism and unfamiliarity among policymakers and regulators, limited government funding, and of course, Schedule 1 restrictions. In this panel, leaders of government and regulatory affairs offices from the psychedelic industry will share their stories about working with policymakers and administrators, and share their predictions for the future.